blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1368061

EP1368061 - FUSION CELLS AND CYTOKINE COMPOSITIONS FOR TREATMENT OF DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.10.2009
Database last updated on 24.08.2024
Most recent event   Tooltip30.09.2011Lapse of the patent in a contracting state
New state(s): CY, TR		published on 02.11.2011  [2011/44]
Applicant(s)For all designated states
OHNO, Tsuneya
201 Newbury Street no 206
Boston, MA 02116 / US
[2008/52]
Former [2003/50]For all designated states
Ohno, Tsuneya
201 Newbury Street no 206
Boston, MA 02116 / US
Inventor(s)01 / see applicant
...
 [2003/50]
Representative(s)Chapman, Paul Gilmour, et al
Marks & Clerk LLP The Beacon
176 St Vincent Street
Glasgow G2 5SG / GB
[N/P]
Former [2003/50]Chapman, Paul Gilmour, et al
Cruikshank & Fairweather, 19 Royal Exchange Square
Glasgow G1 3AE / GB
Application number, filing date01987655.622.10.2001
[2003/50]
WO2001US47057
Priority number, dateUS20000242154P20.10.2000         Original published format: US 242154 P
[2003/50]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0232378
Date:25.04.2002
Language:EN
[2002/17]
Type: A2 Application without search report 
No.:EP1368061
Date:10.12.2003
Language:EN
The application published by WIPO in one of the EPO official languages on 25.04.2002 takes the place of the publication of the European patent application.
[2003/50]
Type: B1 Patent specification 
No.:EP1368061
Date:24.12.2008
Language:EN
[2008/52]
Search report(s)International search report - published on:US27.02.2003
(Supplementary) European search report - dispatched on:EP05.09.2005
ClassificationIPC:A61K45/00, A61K47/00, A01N63/00, C12N5/00, C12N5/06, C12N5/12
[2003/50]
CPC:
C12N5/16 (EP,US); A61K39/0011 (US); A61K39/4615 (EP);
A61K39/4622 (EP); A61K39/464499 (EP); A61P31/00 (EP);
A61P31/12 (EP); A61P31/16 (EP); A61P31/18 (EP);
A61P31/22 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61K2039/5152 (US); A61K2039/5154 (US); A61K2039/5156 (US);
A61K2039/55538 (EP,US); A61K2039/57 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2003/50]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:FUSIONSZELLEN UND ZYTOKIN-ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KRANKHEITEN[2003/50]
English:FUSION CELLS AND CYTOKINE COMPOSITIONS FOR TREATMENT OF DISEASE[2003/50]
French:CELLULES DE FUSION ET COMPOSITIONS CYTOKINIQUES POUR LE TRAITEMENT DE MALADIES[2003/50]
Entry into regional phase16.05.2003National basic fee paid 
16.05.2003Search fee paid 
16.05.2003Designation fee(s) paid 
16.05.2003Examination fee paid 
Examination procedure14.05.2002Request for preliminary examination filed
International Preliminary Examining Authority: US
16.05.2003Examination requested  [2003/50]
17.11.2003Amendment by applicant (claims and/or description)
14.11.2005Despatch of a communication from the examining division (Time limit: M06)
11.05.2006Reply to a communication from the examining division
10.03.2008Cancellation of oral proceeding that was planned for 14.03.2008
10.03.2008Minutes of oral proceedings despatched
14.03.2008Date of oral proceedings
14.03.2008Date of oral proceedings (cancelled)
18.06.2008Communication of intention to grant the patent
24.10.2008Fee for grant paid
24.10.2008Fee for publishing/printing paid
Opposition(s)25.09.2009No opposition filed within time limit [2009/49]
Fees paidRenewal fee
28.10.2003Renewal fee patent year 03
26.10.2004Renewal fee patent year 04
26.10.2005Renewal fee patent year 05
26.10.2006Renewal fee patent year 06
23.04.2008Renewal fee patent year 07
14.10.2008Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.10.200707   M06   Fee paid on   23.04.2008
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT24.12.2008
BE24.12.2008
CY24.12.2008
DK24.12.2008
FI24.12.2008
NL24.12.2008
TR24.12.2008
SE24.03.2009
GR25.03.2009
ES04.04.2009
PT25.05.2009
[2011/43]
Former [2010/47]AT24.12.2008
BE24.12.2008
DK24.12.2008
FI24.12.2008
NL24.12.2008
SE24.03.2009
GR25.03.2009
ES04.04.2009
PT25.05.2009
Former [2009/46]AT24.12.2008
BE24.12.2008
DK24.12.2008
FI24.12.2008
NL24.12.2008
SE24.03.2009
ES04.04.2009
PT25.05.2009
Former [2009/40]AT24.12.2008
BE24.12.2008
FI24.12.2008
NL24.12.2008
SE24.03.2009
ES04.04.2009
PT25.05.2009
Former [2009/37]BE24.12.2008
FI24.12.2008
NL24.12.2008
SE24.03.2009
ES04.04.2009
PT25.05.2009
Former [2009/33]BE24.12.2008
FI24.12.2008
NL24.12.2008
ES04.04.2009
Former [2009/32]BE24.12.2008
FI24.12.2008
NL24.12.2008
Former [2009/25]FI24.12.2008
NL24.12.2008
Documents cited:Search[X]DE19633731  (PETERS JOHANN HINRICH PROF DR [DE]) [X] 1-3,5-12,18,21,26,29-32,34-37,39,41-44,48-50 * the whole document *;
 [XY]WO9846785  (DANA FARBER CANCER INST INC [US]) [X] 1-3,5-8,10,14,18,26,29-31,35,36,39-41,48-50 * the whole document * [Y] 4,19,20,22,27,28;
 [PX]WO0162902  (UNIV EBERHARD KARLS [DE]) [PX] 1-18,21,24-26,29-50* the whole document *;
 [X]  - CAO X ET AL, THERAPY OF ESTABLISHED TUMOUR WITH A HYBRID CELLULAR VACCINE GENERATED BY USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENETICALLY MODIFIED DENDRITIC CELLS, IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, PAGE(S) 616-625, (1999), ISSN 0019-2805, XP002950172 [X] 1 * the whole document *

DOI:   http://dx.doi.org/10.1046/j.1365-2567.1999.00823.x
 [X]  - WANG J ET AL, Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines, JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, PAGE(S) 5516-5524, (1998), ISSN 0022-1767, XP002171426 [X] 1 * the whole document *
 [Y]  - FALLARINO F ET AL, "IMPROVED EFFICACY OF DENDRITIC CELL VACCINES AND SUCCESSFUL IMMUNIZATION WITH TUMOR ANTIGEN PEPTIDE-PULSED PERIPHERAL BLOOD MONONUCLEAR CELLS BY COADMINISTRATION OF RECOMBINANT MURINE INTERLEUKIN-12", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, (19990118), vol. 80, no. 2, ISSN 0020-7136, pages 324 - 333, XP000867038 [Y] 4,19,20,22,27,28 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1097-0215(19990118)80:2<324::AID-IJC25>3.0.CO;2-D
International search[Y]  - LESPAGNARD, L. ET AL., "Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity", INT. J. CANCER, (1998), vol. 76, pages 250 - 258, XP002951123

DOI:   http://dx.doi.org/10.1002/(SICI)1097-0215(19980413)76:2<250::AID-IJC13>3.0.CO;2-G
 [Y]  - GONG, J. ET AL., "Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity", J. IMMUNOL., (2000), vol. 165, pages 1705 - 1711, XP002171429
 [Y]  - GONG, J. ET AL., "Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells", PROC. NATL. ACAD. SCI. USA, (20000314), vol. 97, no. 6, pages 2715 - 2718, XP002170124

DOI:   http://dx.doi.org/10.1073/pnas.050587197
Examination   - AHUJA S. ET AL., "Human dendritic cell (DC)-based anti-infeective therapy: engineering DCs to secrete functional IFN-gamma and IL-12", J. IMMUNOLOGY, US, (1998), vol. 161, pages 868 - 876
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.